ZBH:NYSE (USA) Also trade in: Germany Switzerland UK

Zimmer Biomet Holdings Inc

$ 124.61 1.85 (1.5%)
On watch
Volume: 821,331 Avg Vol (1m): 1,176,966
Market Cap $: 25.58 Bil Enterprise Value $: 33.98 Bil
P/E (TTM): 14.35 P/B: 2.26
Earnings Power Value -8.9
Net Current Asset Value -41.32
Tangible Book -29.45
Projected FCF 91.79
Median P/S Value 117.84
Graham Number 0
Peter Lynch Value 0
DCF (FCF Based) 0
DCF (Earnings Based) 0
YTD (-%)

Financial Strength : 5/10

Current vs industry vs history
Cash-to-Debt 0.06
Equity-to-Asset 0.47
Debt-to-Equity 0.79
Debt-to-EBITDA 8.44
Interest Coverage 3.88
Piotroski F-Score 5
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 2.15
DISTRESS
GREY
SAFE
Beneish M-Score -2.81
Not Manipulator
Manipulator
WACC vs ROIC %
ROIC 7.52%
WACC 10.21%

Profitability & Growth : 8/10

Current vs industry vs history
Operating Margin % 14.13
Net Margin % -4.78
ROE % -3.20
ROA % -1.48
ROC (Joel Greenblatt) % 0.44
3-Year Total Revenue Growth Rate 9.80
3-Year Total EBITDA Growth Rate -2.80

» ZBH's 30-Y Financials

Financials (Next Earnings Date: 2019-04-26)

Guru Trades Click for details

» Details

Insider Trades

SEC Filings

Gurus Latest Trades with NYSE:ZBH

» Interactive Chart

Peter Lynch Chart

Business Description

Industry Medical Devices » Medical Devices    NAICS : 339113    SIC : 3842
Compare NAS:ALGN NYSE:EW LSE:SN. NAS:ABMD NYSE:TFX XSWX:SOON NYSE:VAR SZSE:300003 OCSE:WDH XPAR:DIM ASX:COH NYSE:BSX LSE:CTEC NZSE:FPH NYSE:GMED OCSE:AMBU B NAS:IART OCSE:GN NAS:MASI OSTO:EKTA B
Traded in other countries ZIM.Germany 0QQD.UK
Address 345 East Main Street, Warsaw, IN, USA, 46580
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. It distributes and sells its products to hospitals and clinics worldwide under brand names like NexGen, Zimmer, VerSys, SoPlus, and Pulsavac.

Ratios

Current vs industry vs history
PE Ratio (TTM) 14.35
Forward PE Ratio 15.75
N/A
PE Ratio without NRI 14.35
Price-to-Owner-Earnings 85.36
PB Ratio 2.26
PS Ratio 3.22
Price-to-Free-Cash-Flow 19.56
Price-to-Operating-Cash-Flow 14.64
EV-to-EBIT 1866.89
EV-to-EBITDA 32.11
EV-to-Revenue 4.27
Shiller PE Ratio 26.47
Current Ratio 1.83
Quick Ratio 0.90
Days Inventory 347.94
Days Sales Outstanding 58.70
Days Payable 58.25

Dividend & Buy Back

Current vs industry vs history
Dividend Yield % 0.77
3-Year Dividend Growth Rate (Per Share) 2.90
Forward Dividend Yield % 0.78
N/A
Yield-on-Cost (5-Year) % 0.94
3-Year Share Buyback Rate -0.20

Valuation & Return

Current vs industry vs history
Price-to-Projected-FCF 1.36
Price-to-Median-PS-Value 1.06
Earnings Yield (Joel Greenblatt) % 0.05
Forward Rate of Return (Yacktman) % 5.65

More Statistics

Revenue (TTM) (Mil) $ 7,932.9
EPS (TTM) $ 8.7
Beta 1.41
Volatility % 28.56
52-Week Range $ 96.99 - 134.55
Shares Outstanding (Mil) 204.58

Analyst Estimate

Piotroski F-Score Details

Piotroski F-Score 5
Positive ROA N
Positive CFROA Y
Higher ROA yoy N
CFROA > ROA Y
Lower Leverage yoy Y
Higher Current Ratio yoy Y
Less Shares Outstanding yoy N
Higher Gross Margin yoy N
Higher Asset Turnover yoy Y